The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.
